Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vanda Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Vanda Pharmaceuticals Inc.’s stock price such as:

• Vanda Pharmaceuticals Inc.’s current stock price and volume
• Why Vanda Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for VNDA from analysts
• VNDA’s stock price momentum as measured by its relative strength

About Vanda Pharmaceuticals Inc. (VNDA)

Before we jump into Vanda Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company’s pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Want to learn more about Vanda Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vanda Pharmaceuticals Inc..

Vanda Pharmaceuticals Inc.’s Stock Price as of Market Close

As of December 02, 2025, 1:48 PM, CST, Vanda Pharmaceuticals Inc.’s stock price was $4.955.

Vanda Pharmaceuticals Inc. is down 1.29% from its previous closing price of $5.020.

During the last market session, Vanda Pharmaceuticals Inc.’s stock traded between $4.900 and $5.040. Currently, there are approximately 59.09 million shares outstanding for Vanda Pharmaceuticals Inc..

Vanda Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vanda Pharmaceuticals Inc. Stock Price History

Vanda Pharmaceuticals Inc.’s (VNDA) price is currently down 7.56% so far this month.

During the month of December, Vanda Pharmaceuticals Inc.’s stock price has reached a high of $5.350 and a low of $4.900.

Over the last year, Vanda Pharmaceuticals Inc. has hit prices as high as $5.700 and as low as $3.809. Year to date, Vanda Pharmaceuticals Inc.’s stock is up 3.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vanda Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were analysts who downgraded Vanda Pharmaceuticals Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Vanda Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vanda Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vanda Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vanda Pharmaceuticals Inc. (VNDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Vanda Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Vanda Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 0.37%, which translates to a Momentum Score of 61 and is considered to be Strong.

Want to learn more about how Vanda Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vanda Pharmaceuticals Inc. Stock Price: Bottom Line

As of December 2, 2025, Vanda Pharmaceuticals Inc.’s stock price is $4.955, which is down 1.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vanda Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.